Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and PD-1 Inhibitors for Managing Arterioportal Shunt in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Cohort Study
Guanxiong Liu,Duo Zhu,Quansheng He,Churen Zhou,Li He,Zhengran Li,Zaibo Jiang,Mingsheng Huang,Boyang Chang,Chun Wu
DOI: https://doi.org/10.2147/jhc.s456460
2024-07-13
Journal of Hepatocellular Carcinoma
Abstract:Guanxiong Liu, &ast Duo Zhu, &ast Quansheng He, &ast Churen Zhou, Li He, Zhengran Li, Zaibo Jiang, Mingsheng Huang, Boyang Chang, Chun Wu Department of Interventional Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, People's Republic of China &astThese authors contributed equally to this work Correspondence: Boyang Chang; Chun Wu, Email ; Purpose: This study aimed to assess the effectiveness and safety of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib (LEN) and PD-1 inhibitors in treating arterioportal shunt (APS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Patients and Methods: Conducted retrospectively, the study enrolled 54 HCC patients with APS and PVTT treated with HAIC, LEN, and PD-1 inhibitors at our center between January 2021 and October 2023. APS improvement, APS recanalization, tumor response, PVTT response rate, overall survival (OS), intrahepatic progression-free survival (InPFS), and adverse events were evaluated. Results: APS improvement was observed in 42 patients (77.8%), with all improvement occurring within two treatment sessions. Complete APS occlusion was achieved in 40 patients (74.1%), and no recanalization occurred. The best objective response rate (ORR) and ORR after two HAIC sessions were 74.1% and 66.7%, respectively. The best PVTT response and PVTT response after two HAIC sessions were 98.1% and 94.4%, respectively. The median OS and InPFS were 10.0 months and 5.0 months, respectively. OS and InPFS were longer in patients with APS occlusion compared to those without (OS 12.1 vs 4.4 months, P< 0.001, InPFS 6.2 vs 2.3 months, P=0.049). ALBI grade, extrahepatic spread, APS disappearance were potential prognostic factors for OS, while APS grade and extrahepatic spread being independently associated with InPFS. No treatment-related mortality occurred. Conclusion: Combining HAIC with LEN and PD-1 inhibitors proves to be both effective and safe in managing APS in HCC with PVTT, potentially improving patient survival. Keywords: hepatocellular carcinoma, shunt, portal vein tumor thrombus, hepatic arterial infusion chemotherapy, combination therapy Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. 1 In China, portal vein tumor thrombus (PVTT) is diagnosed in 44% to 62.2% of HCC patients. 2,3 Arterioportal shunt (APS) occurs in 28.8%-63.2% of advanced HCC cases, often in conjunction with PVTT. 4,5 APS is typically considered an adverse prognostic factor, as severe APS can exacerbate portal hypertension, leading to severe complications like ruptured gastro-esophageal varices, refractory ascites. 6–9 Moreover, HCC patients with moderate or severe APS are ineligible for transarterial chemoembolization (TACE). Therefore, the effective treatment of shunt tracts to alleviate portal pressure and facilitate subsequent tumor embolization is critical. Transcatheter embolization is the common choice for APS in clinical practice. Various embolic agents have been used to occlude APS, such as polyvinyl alcohol (PVA), gelatin sponge, microsphere, absolute ethanol, coils, N-butyl-2-cyanoacrylate (NBCA). 10–17 However, each of these embolic agents has drawbacks. Gelatin sponge is typically reabsorbed within a few weeks, 18,19 leading to a high recanalization rate. Coils are suitable for simple shunts but not for those caused by tumors. NBCA demands advanced operator skills with a risk of ectopic embolization. Additionally, fast blood flow in severe APS often limits precise embolization due to poor shunt visualization. Hence, there is an urgent need for a safe and effective treatment to address this current dilemma. Recent evidence supports the survival benefits of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin for advanced HCC. 20,21 The Barcelona Clinic Liver Cancer staging system (BCLC) proposes systemic therapy for HCC with PVTT. 22 Given the proven effectiveness of both HAIC and systemic therapy in advanced HCC companied with PVTT, 21,23,24 it's reasonable to consider this combination for the treatment of APS in HCC patients with PVTT. To the best of our knowledge, limited reports exist regarding HAIC combined with lenvatinib (LEN) and PD-1 inhibitors for this condition. Thus, we conducted a retrospective study to evaluate the effectiveness and safety of this integrated therapy for treating APS in HCC patients with PVTT. This study was approved by the Ethics Committee of our center (II2024-050-01). Informed consent was waived due to the retrospective study nature. Between January 2021 and October 2023 -Abstract Truncated-
oncology